JPT PEPTIDE TECHNOLOGIES GMBH

JPT Peptide Technologies GmbH specializes in the research, development, and production of synthetic peptides for biomedical and pharmaceutical applications. Leveraging advanced solid-phase peptide synthesis and high-purity purification technologies, the company delivers custom peptide sequences, modified peptides, and peptide-based research reagents with precise structural control. Their technical expertise includes sequence design, cyclization, non-natural amino acid incorporation, and conjugation chemistries such as PEGylation and fluorescent labeling, supporting applications in drug discovery, diagnostic development, and molecular biology research. Differentiators include stringent quality control protocols, GMP-aligned production practices, and scalable manufacturing capabilities tailored to preclinical and early clinical-stage needs. No award history is available to infer specific agency engagements or government contract performance. Consequently, there is no demonstrable track record of direct work with federal agencies or public sector programs. The company operates within NAICS 325414, which encompasses the manufacturing of pharmaceutical preparations, specifically focusing on active pharmaceutical ingredients and research-grade biologics. In practice, this translates to a niche market position as a specialized supplier of peptide building blocks for academic, biotech, and pharmaceutical R&D environments. Their market positioning is that of a high-precision contract manufacturer serving early-stage innovation pipelines rather than commercial-scale drug production. JPT Peptide Technologies GmbH is structured as a limited liability company (2L) based in Berlin, Germany. The firm holds no government certifications, including none related to U.S. federal contracting programs such as 8(a), HUBZone, or small business status. Its geographic presence is confined to Germany, with no indication of U.S.-based operations or registered federal procurement presence. The company functions as a specialized supplier within the global life sciences supply chain, with no public evidence of direct engagement in government-funded research or procurement initiatives.